AccurKardia vs Biobeat (2026)
Two cardiac and vital sign products that differ on whether the data already exists. AccurKardia interprets the electrocardiogram, cleared Class II software producing near automated interpretation and deliberately device agnostic across sources, aimed at an organisation drowning in tracings nobody has time to read. Biobeat creates the data instead, putting wearable continuous monitors on patients who are otherwise checked every few hours, with a genuinely strong progressive clearance record for cuffless measurement and the widest setting coverage in its category. The dividing line is whether your failure is interpretation capacity or observation frequency. Ask each about subgroups and the questions differ: electrocardiogram morphology varies with sex and body habitus, while optical measurement varies with skin tone, and Biobeat's readings feed automated alerts.
- It analyses the electrocardiogram itself, cleared Class II software producing near automated interpretation and deliberately device agnostic across ECG sources.
- The input is a tracing the health system already captures, so the constraint it addresses is interpretation capacity rather than data collection.
- For an organisation with volumes of unread or slowly read tracings, that is the bottleneck and this is aimed at it.
- It changes what data exists, putting wearable continuous monitors on patients who are otherwise checked intermittently, with a progressive clearance record for cuffless measurement.
- Setting coverage is the widest in its category, spanning general wards, step down and home monitoring on one platform.
- Continuous vital signs reach deterioration that a periodic tracing will never show, because the event happens between checks.
This comparison is published by AI Health Index, an independent research platform that compares healthcare AI vendors objectively. AccurKardia and Biobeat are each graded against the same capability taxonomy, from each vendor's own public materials and the regulatory record, under the AI Health Index verification standard. No vendor pays for placement, and no vendor has reviewed this page. How this evidence is graded
Plain facts
| Fact | AccurKardia | Biobeat |
|---|---|---|
| Primary category | Diagnostics & Genomics | Inpatient Deterioration & Risk Monitoring |
| Founded | 2019 | 2016 |
| Headquarters | New York, New York, United States | Petah Tikva, Israel |
| Website | accurkardia.com | bio-beat.com |
Side by Side
Each record in one paragraph
Written to be quoted whole. Each paragraph states what the AI Health Index verified about the vendor, with the caveats attached. Generated from this pair’s live capability grades, so it moves when a grade moves.
The AI Health Index awards AccurKardia its top capability grade on AI Centrality and FDA and Regulatory Status. Set against Biobeat, AccurKardia grades higher on several axes, including AI Centrality, Autonomy and Oversight Model and Model and Technology Transparency. Its thinnest published disclosure sits on Model Supply Chain Disclosure. Grades reflect evidence the AI Health Index could verify at the last review, so a low grade records disclosure the vendor has not published rather than a capability it has been shown to lack.
Source: AI Health Index, August 2026
The AI Health Index awards Biobeat its top capability grade on FDA and Regulatory Status. Set against AccurKardia, Biobeat grades higher on Deployment Model and Data Residency and Setting and Specialty Coverage. Its thinnest published disclosure sits on Model Supply Chain Disclosure and AI Liability and Recourse. Grades reflect evidence the AI Health Index could verify at the last review, so a low grade records disclosure the vendor has not published rather than a capability it has been shown to lack.
Source: AI Health Index, August 2026
Questions buyers ask
Should we choose AccurKardia or Biobeat?
On the axes where the AI Health Index separates them, AccurKardia grades higher on several axes, including AI Centrality, Autonomy and Oversight Model and Model and Technology Transparency, and Biobeat grades higher on Deployment Model and Data Residency and Setting and Specialty Coverage. AccurKardia leads on the greater share of scored axes, but the split means the decision turns on which constraint is binding rather than on an overall winner.
Where do AccurKardia and Biobeat differ most?
The widest separation the AI Health Index records between AccurKardia and Biobeat is on AI Centrality, where AccurKardia grades A and Biobeat grades C. That axis sits in the AI Capability group, so it should carry the most weight for a buyer whose binding constraint is how much of the work the model itself is trusted to do.
Where do AccurKardia and Biobeat grade the same?
The AI Health Index grades AccurKardia and Biobeat the same on several axes, including Model Supply Chain Disclosure, AI Safety and PHI Stewardship and HIPAA and BAA Posture. Neither holds an advantage the index can evidence on those axes, so they should not carry weight in a selection between these two.
What have AccurKardia and Biobeat not disclosed?
At the last review, at least one of AccurKardia and Biobeat published thin or absent detail on Model Supply Chain Disclosure and AI Liability and Recourse. The AI Health Index treats an absent disclosure as a gap in the public record rather than a failure of the product, so these are the axes to get in writing during diligence instead of inferring from the grade.
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Remote Monitoring & Chronic Care page.
Neither vendor publishes subgroup or population performance, and the exposure differs by modality in a way buyers should hold: electrocardiogram morphology varies with sex, age and body habitus, while optical vital sign measurement is known to perform differently across skin tones, and Biobeat's measurements feed automated early warning alerts rather than only a display. Ask each for performance stratified accordingly. Biobeat publishes no named record system integration, no attestation and no retention position. Neither publishes pricing.